Nepafenac 0.3% Two Study

PHASE2CompletedINTERVENTIONAL
Enrollment

1,342

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Cataract
Interventions
DRUG

Nepafenac Ophthalmic Suspension, 0.3%

Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.

DRUG

Nepafenac Ophthalmic Suspension, 0.1%

Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.

OTHER

Nepafenac Vehicle 0.3%

Nepafenac Vehicle 0.3%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.

Trial Locations (1)

76134

Contact Alcon Call Center for Trial Locations, Fort Worth

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Alcon Research

INDUSTRY

NCT01318499 - Nepafenac 0.3% Two Study | Biotech Hunter | Biotech Hunter